SWOG clinical trial number
S1300
A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit from Crizotinib Monotherapy
Closed
Phase
Accrual
1%
Abbreviated Title
Rand Ph II of Crizotinib + Pem vs Pem in ALK+ NSCLC Pts Progressing Post Crizotinib
Status Notes
This study will permanently close to accrual on September 1, 2016 at 11:59 p.m. Pacific.
Activated
08/01/2014
Closed
09/01/2016
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lung Cancer
Treatment
Pemetrexed
Crizotinib
Eligibility Criteria Expand/Collapse
Stage IV, ALK positive, non-squamous non-small cell lung cancer; progressed after attaining clinical benefit with crizotinib (at 250 mg BID for at least 90 days); pemetrexed naive; measurable disease; no brain mets (except for asymptomatic controlled mets off steroids or anticonvulsants for 14 days; palliative RT to non-target lesions ok; no major surgery within 28 days prior to reg; no exposure to HSP90 inhibitors or non-crizotinib ALK inhibitors; offered participation in translational medicine studies; ANC >/= 1500, PLT >/= 100,000, Hgb >/= 9, bili </= 2 x IULN, either AST or ALT </= 2.5 x IULN, estimated or measured glomerular filtration rate >/= 45, testosterone obtained for male pts; Zubrod 0-2; able to swallow capsules; QTC interval </= 480 msec on EKG (pts w/congenital long QT syndrome not eligible).
Publication Information Expand/Collapse
2014
PMid: PMID24176733 | PMC number: PMC4586161
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open